Clinical Trial Update: Satavaptan Dose-Ranging Study in the Prevention of Ascites [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of satavaptan for prevention of ascites in liver cirrhosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Liver Cirrhosis

Drugs mentioned

• Satavaptan (satavaptan)

Snippet

Sponsor: Sanofi | Conditions: Ascites, Liver Cirrhosis | Phase 2 | Status: COMPLETED